Does the Diabetes Alliance Program Plus Reduce Hospitalisations in Patients with Type 2 Diabetes Attending Primary Care Practices? A Target Trial Protocol for Emulating a Cluster Trial Using Linked General Practice and Tertiary Health Data
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Effective management of type 2 diabetes is an increasing challenge for health services globally. Integrated care, targeted at increasing capacity in primary care for earlier intervention in type 2 diabetes, may reduce adverse health outcomes, with benefits accrued over time. This protocol aims to describe a causal approach for the evaluation of a specialist-led integrated model of care delivered in Australian general practices, using linked administrative health data.
Methods
This protocol outlines an observational cohort study using the Lumos data asset (New South Wales Health), linking general practice and hospital data. It follows the target trial framework, emulating a parallel cluster-randomised trial, and applies the estimands framework proposed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. It describes the data structure and statistical analysis plan required for causal inference. The primary causal estimand is the effect of the Diabetes Alliance Program Plus, an integrated care intervention, on all-cause hospitalisation rates for adults actively attending general practice with current or newly diagnosed type 2 diabetes over a 5-year follow-up period.
Discussion
This protocol applies the target trial framework to emulate a parallel cluster-randomized trial of the Diabetes Alliance Program Plus using linked administrative data. This approach addresses confounding and selection bias inherent in observational evaluations of practice-level interventions and will generate robust real-world evidence to inform policy regarding type 2 diabetes management in primary care settings.
Trial registration
ACTRN12622001438741; 10th November 2022, retrospectively registered: https://www.anzctr.org.au/ACTRN12622001438741.aspx .
